Research programme: botulinum toxin-based therapeutics - Allergan/ Meditox

Drug Profile

Research programme: botulinum toxin-based therapeutics - Allergan/ Meditox

Alternative Names: botulinum toxin; botulinum toxin B - Medytox

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medy-Tox
  • Class Bacterial proteins; Bacterial toxins
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Spasm

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spasm in South Korea (Parenteral, Injection)
  • 25 Sep 2013 Neurotoxin-based therapeutics licensed to Allergan worldwide (excluding Korea)
  • 14 Oct 2008 Preclinical development is ongoing with Medy-Tox
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top